Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 334Carcinoma, Non-Small-Cell Lung 262Ovarian Neoplasms 177Lung Neoplasms 129Neoplasms 92Fallopian Tube Neoplasms 77Carcinoma, Ovarian Epithelial 63Neoplasm Metastasis 59Esophageal Neoplasms 58Stomach Neoplasms 49Head and Neck Neoplasms 45Squamous Cell Carcinoma of Head and Neck 44Triple Negative Breast Neoplasms 40Endometrial Neoplasms 37Adenocarcinoma of Lung 32Urinary Bladder Neoplasms 28Esophageal Squamous Cell Carcinoma 26Unspecified Adult Solid Tumor, Protocol Specific 24Uterine Cervical Neoplasms 23Carcinoma 23Melanoma 22Breast Neoplasms, Male 22Small Cell Lung Carcinoma 20Prostatic Neoplasms 20Adenocarcinoma Of Esophagus 20Recurrence 19Parkinson Disease 4, Autosomal Dominant Lewy Body 19Brenner Tumor 18Adenocarcinoma, Bronchiolo-Alveolar 18Peritoneal Neoplasms 16

Interventions

camrelizumab 1Paclitaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Esophageal Cancer × Paclitaxel × Clear all
NCT03691090 2022-12-07

Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
596 enrolled
Gastrointestinal

Advanced Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡